# Vertex Kidney Drug Povetacicept Achieves Breakthrough Phase 3 Results, FDA Filing Expected This Month

*2026-03-11 05:02 UTC · Science · 1 min read*

> Vertex's povetacicept cut proteinuria by 52% in Phase 3 kidney disease trial, with FDA filing expected by end of March.

Vertex Pharmaceuticals reported landmark Phase 3 results for povetacicept, a dual BAFF/APRIL inhibitor targeting IgA nephropathy, a progressive kidney disease affecting millions worldwide. In the Week 36 interim analysis of the RAINIER trial, patients achieved a 52% reduction in proteinuria from baseline — a 49.8% improvement over placebo (P<0.0001). Vertex shares climbed more than 5% on the news.

Secondary endpoints were equally striking: the drug reduced serum Gd-IgA1 levels by 77.4% and achieved hematuria resolution in 85.1% of treated patients, both with high statistical significance versus placebo.

The company plans to complete its full BLA submission to the FDA by the end of March, using a priority review voucher to cut the review timeline from ten to six months. If approved, povetacicept would become a first-in-class treatment for IgA nephropathy, a disease with limited options that can progress to kidney failure.

## Sources

- [biopharmadive.com](https://www.biopharmadive.com/news/vertex-povetacicept-iga-nephropathy-study-results/814253/)
- [news.vrtx.com](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-week-36-interim-analysis-results)

---
TechTools News · https://techtools.cz/tools/news/article/712-vertex-kidney-drug-povetacicept-achieves-breakthrough-phase-3-results-fda
Česká verze: https://techtools.cz/tools/news/clanek/727-lek-povetacicept-od-vertex-dosahl-prulomovych-vysledku-ve-studii-faze-3-zadost
